Autologous CD34+ hematopoietic stem and progenitor cells (CD34+ HSPCs)

Autologous CD34+ hematopoietic stem and progenitor cells (HSPCs) are a population of multipotent cells harvested from a patient's own bone marrow or mobilized peripheral blood [1, 2]. These cells are defined by the expression of the CD34 surface glycoprotein, a sialomucin that facilitates cell adhesion and homing to the bone marrow niche [3, 4]. CD34+ HSPCs are essential for hematopoiesis, as they possess the unique ability to self-renew and differentiate into all mature blood cell types, including erythrocytes, leukocytes, and platelets [5]. In the context of advanced therapeutics, these cells serve as the primary substrate for ex vivo gene therapies and genome editing [6]. The therapeutic process involves the isolation of CD34+ cells, followed by genetic modification—such as the insertion of a functional gene via lentiviral vectors or the precise editing of genomic loci using CRISPR/Cas9—and subsequent reinfusion into the patient [1, 7]. This approach is currently utilized to provide potentially curative treatments for a range of genetic disorders, including sickle cell disease, beta-thalassemia, and various primary immunodeficiencies [8, 9]. References: [1] FDA (2023) Casgevy Approval; [2] FDA (2023) Lyfgenia Approval; [3] NIH (2023) CD34 Protein Function; [4] PubMed (2017) CD34 Homing; [5] StatPearls (2023) Hematopoiesis; [6] NIH (2024) Gene Therapy Overview; [7] NEJM (2021) CRISPR-Cas9 Gene Editing for SCD; [8] FDA (2022) Zynteglo Approval; [9] NIH (2022) SCID Gene Therapy.

Other names

CD34+ cellsHematopoietic stem and progenitor cellsHSPCsAutologous hematopoietic stem cellsBone marrow stem cellsMobilized peripheral blood CD34+ cells

Ex vivo genetic modification via gene addition (lentiviral vectors) or gene editing (CRISPR/Cas9) followed by autologous transplantation to restore or correct hematopoietic function [1, 2]. Mobilization from bone marrow to peripheral blood for collection [6, 7]. Myeloablative conditioning to create space for engraftment [8].